Clinical trials: Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
Background: Previously we have demonstrated induction of tumor antigen and tumor suppressor gene expression in lung cancer cells following exposure to the DNA demethylating agent, Decitabine (DAC).
- Conditions
- Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas
- Trial name
- NCT00037817
- Testing
- Decitabine, Depsipeptide, Celecoxib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Thoracic Sarcomas, Thorasic Cancers
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background: During recent years, cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X genes), have emerged as attractive targets for cancer immunotherapy.
- Conditions
- Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Sarcoma
- Trial name
- NCT02054104
- Testing
- H1299 cell lysates, Cyclophosphamide, Celecoxib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Background: Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.
- Conditions
- Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS
- Trial name
- NCT00242723
- Where
- United States
- Volunteers
- 1,559 people
- Sponsor
- National Cancer Institute (NCI)